BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 16310719)

  • 1. Opioid-induced or pain relief-reduced symptoms in advanced cancer patients?
    Mercadante S; Villari P; Ferrera P; Casuccio A
    Eur J Pain; 2006 Feb; 10(2):153-9. PubMed ID: 16310719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain.
    Tawfik MO; Bryuzgin V; Kourteva G;
    Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
    Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
    Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit.
    Mercadante S; Ferrera P; Villari P; Casuccio A; Intravaia G; Mangione S
    J Pain Symptom Manage; 2009 Apr; 37(4):632-41. PubMed ID: 19345298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimization of opioid therapy for preventing incident pain associated with bone metastases.
    Mercadante S; Villari P; Ferrera P; Casuccio A
    J Pain Symptom Manage; 2004 Nov; 28(5):505-10. PubMed ID: 15504626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus.
    Pergolizzi JV; Mercadante S; Echaburu AV; Van den Eynden B; Fragoso RM; Mordarski S; Lybaert W; Beniak J; Orońska A; Slama O;
    Curr Med Res Opin; 2009 Jun; 25(6):1517-28. PubMed ID: 19435402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids.
    Mercadante S; Intravaia G; Villari P; Ferrera P; Riina S; David F; Mangione S
    Clin J Pain; 2007; 23(9):793-8. PubMed ID: 18075407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids.
    Enting RH; Oldenmenger WH; van der Rijt CC; Wilms EB; Elfrink EJ; Elswijk I; Sillevis Smitt PA
    Cancer; 2002 Jun; 94(11):3049-56. PubMed ID: 12115396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study.
    Mercadante S; Porzio G; Ferrera P; Aielli F; Verna L; Tirelli W; Villari P; Casuccio A
    Clin Ther; 2009 Oct; 31(10):2134-8. PubMed ID: 19922884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain.
    Glare P; Walsh D; Sheehan D
    Am J Hosp Palliat Care; 2006; 23(3):229-35. PubMed ID: 17060284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
    Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
    Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Codeine/acetaminophen and hydrocodone/acetaminophen combination tablets for the management of chronic cancer pain in adults: a 23-day, prospective, double-blind, randomized, parallel-group study.
    Rodriguez RF; Castillo JM; Del Pilar Castillo M; Nuñez PD; Rodriguez MF; Restrepo JM; Rodriguez JM; Ortiz Y; Angel AM
    Clin Ther; 2007 Apr; 29(4):581-7. PubMed ID: 17617281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid escalation in patients with cancer pain: the effect of age.
    Mercadante S; Ferrera P; Villari P; Casuccio A
    J Pain Symptom Manage; 2006 Nov; 32(5):413-9. PubMed ID: 17085267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral transmucosal fentanyl citrate for the treatment of migraine headache pain in outpatients: a case series.
    Landy SH
    Headache; 2004 Sep; 44(8):762-6. PubMed ID: 15330821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
    Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid switching between transdermal fentanyl and methadone in cancer patients.
    Mercadante S; Ferrera P; Villari P; Casuccio A
    J Clin Oncol; 2005 Aug; 23(22):5229-34. PubMed ID: 16051965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study.
    Portenoy RK; Farrar JT; Backonja MM; Cleeland CS; Yang K; Friedman M; Colucci SV; Richards P
    Clin J Pain; 2007 May; 23(4):287-99. PubMed ID: 17449988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.